Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CG Oncology, Inc. (CGON – Research Report) and Intellia Therapeutics (NTLA – Research Report) with bullish sentiments.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CG Oncology, Inc. (CGON)
JonesTrading analyst Soumit Roy maintained a Buy rating on CG Oncology, Inc. today and set a price target of $85.00. The company’s shares closed last Monday at $58.81.
According to TipRanks.com, Roy is ranked 0 out of 5 stars with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CG Oncology, Inc. with a $83.17 average price target, which is a 45.6% upside from current levels. In a report issued on February 19, Cantor Fitzgerald also maintained a Buy rating on the stock with a $100.00 price target.
See the top stocks recommended by analysts >>
Intellia Therapeutics (NTLA)
William Blair analyst Myles Minter upgraded Intellia Therapeutics to Buy today. The company’s shares closed last Monday at $15.00.
According to TipRanks.com, Minter is a 5-star analyst with an average return of
Currently, the analyst consensus on Intellia Therapeutics is a Moderate Buy with an average price target of $17.10, implying a 24.0% upside from current levels. In a report issued on February 26, TD Cowen also maintained a Buy rating on the stock.
